Form 8-K - Current report:
SEC Accession No. 0001437749-25-020335
Filing Date
2025-06-13
Accepted
2025-06-13 16:53:33
Documents
13
Period of Report
2025-06-12
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tgtx20250613_8k.htm   iXBRL 8-K 42885
  Complete submission text file 0001437749-25-020335.txt   174124

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tgtx-20250612.xsd EX-101.SCH 3579
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tgtx-20250612_def.xml EX-101.DEF 11424
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tgtx-20250612_lab.xml EX-101.LAB 15310
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tgtx-20250612_pre.xml EX-101.PRE 11584
15 EXTRACTED XBRL INSTANCE DOCUMENT tgtx20250613_8k_htm.xml XML 2854
Mailing Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 (212) 554-4484
TG THERAPEUTICS, INC. (Filer) CIK: 0001001316 (see all company filings)

EIN.: 363898269 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32639 | Film No.: 251047416
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)